Profile data is unavailable for this security.
About the company
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas. The Company's products are antibody drug conjugates (ADCs) SKB264, A166 and others. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancer and other diseases.
- Revenue in HKD (TTM)1.70bn
- Net income in HKD-817.92m
- Incorporated2016
- Employees1.87k
- LocationSichuan Kelun-Biotech Biopharmaceutical Co LtdNo. 666 Xinhua Avenue, Chengdu Cross-StrCHENGDU ChinaCHN
- Websitehttps://www.kelun-biotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genscript Biotech Corp | 4.31bn | 644.58m | 26.33bn | 5.77k | 39.55 | 0.7597 | 44.96 | 6.10 | 0.3044 | 11.44 | 2.02 | 15.85 | 0.1259 | 5.94 | 4.39 | 774,704.90 | 0.3949 | -9.75 | 0.4933 | -13.19 | 51.78 | 52.05 | 3.14 | -46.54 | 1.90 | 1.18 | 0.0471 | -- | 6.07 | 16.81 | -115.90 | -- | 5.78 | -- |
| TransThera Sciences (Nanjing) Inc | 0.00 | -268.52m | 27.43bn | 121.00 | -- | 41.38 | -- | -- | -0.6766 | -0.6766 | 0.00 | 1.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.89 | -- | 0.0052 | -- | -100.00 | -- | 20.03 | -- | -- | -- |
| Shanghai Bao Pharmaceuticals Co Ltd | 52.85m | -430.66m | 54.28bn | -- | -- | 53.87 | -- | 1,027.07 | -1.32 | -1.32 | 0.1621 | 3.09 | -- | -- | -- | -- | -- | -- | -- | -- | 97.96 | -- | -814.93 | -- | 2.07 | -- | 0.2168 | -- | -11.11 | -- | -127.21 | -- | -- | -- |
| Akeso Inc | 2.84bn | -958.18m | 97.00bn | 3.53k | -- | 12.97 | -- | 34.11 | -1.09 | -1.09 | 3.25 | 8.12 | 0.2115 | 0.7726 | 3.95 | 936,947.80 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.70bn | -817.92m | 97.61bn | 1.87k | -- | 17.19 | -- | 57.43 | -3.65 | -3.65 | 7.54 | 24.35 | 0.3067 | 4.93 | 13.37 | 925,245.40 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| WuXi Biologics (Cayman) Inc | 22.71bn | 4.75bn | 165.50bn | 12.55k | 35.72 | 3.20 | 21.97 | 7.29 | 1.12 | 1.12 | 5.42 | 12.51 | 0.3442 | 6.36 | 3.06 | 1,806,232.00 | 8.45 | 7.98 | 10.57 | 9.95 | 42.65 | 42.71 | 24.54 | 25.82 | 2.69 | -- | 0.0943 | 0.00 | 9.63 | 36.21 | -1.28 | 27.05 | 3.97 | -- |
Data as of Feb 13 2026. Currency figures normalised to Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD
16.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 10 Dec 2025 | 8.32m | 5.11% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.68m | 2.26% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 2.54m | 1.56% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 2.39m | 1.47% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 2.16m | 1.33% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.07m | 1.27% |
| BOCHK Asset Management Ltd.as of 30 Jun 2025 | 1.83m | 1.13% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2025 | 1.34m | 0.82% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 1.13m | 0.69% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 987.90k | 0.61% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
